{"prompt": "['MC1752', '34', 'CTCAE', 'System/Organ/Class', 'ADVERSE', '(SOC)', 'EVENTS/SYMPTOMS', 'Avelumab', 'Permanently discontinue avelumab therapy', '1.0 to 2 mg/kg/day', 'prednisone or equivalent', 'Recurrence of same Grade 3', 'Add prophylactic antibiotics for opportunistic infections', 'irAEs', 'Specialty consult as appropriate', 'If improves to Grade < 1:', 'Taper steroids over at least 1 month.', 'Permanently discontinue avelumab therapy', '1.0 to 2 mg/kg/day', 'prednisone or equivalent and/or other immunosuppressant as', 'needed', 'Grade 4', 'Add prophylactic antibiotics for opportunistic infections', 'Specialty consult.', 'If improves to Grade 1:', 'Taper steroids over at least 1 month', 'Requirement for 10 mg per day', 'or greater prednisone or', 'equivalent for more than 12', 'weeks for reasons other than', 'hormonal replacement for', 'Permanently discontinue avelumab therapy', 'adrenal insufficiency', 'Specialty consult', 'Persistent Grade 2 or 3 irAE', 'lasting 12 weeks or longer', 'Abbreviations: ACTH=adrenocorticotropic hormone; ADL=activities of daily living; ALT=alanine aminotransferase;', 'AST=aspartate aminotransferase; BNP=B-type natriuretic peptide; CK-MB=creatine kinase MB; CT= computed', 'tomography; FSH=follicle-stimulating hormone; GH=growth hormone; IGF-1=insulin-like growth factor 1; irAE=immune', 'related adverse event; IV=intravenous; LH=luteinizing hormone; MRI=magnetic resonance imaging; NCI CTCAE=National', 'Cancer Institute Common Terminology Criteria for Adverse Events; PRL=prolactin;T4=thyroxine; TSH=thyroid stimulating', 'hormone; ULN=upper limit of normal.', 'NOTE: If anvelumab therapy is delayed for more than 28 days then discontinue avelumab therapy', 'Since inhibition of PD-L1 stimulates the immune system, irAEs may occur. Treatment', 'of irAEs is mainly dependent upon severity (NCI-CTCAE grade):', 'Grade 1 to 2: treat symptomatically or with moderate dose steroids, more frequent monitoring', 'Grade 1 to 2 (persistent): manage similar to high grade AE (Grade 3 to 4)', 'Grade 3 to 4: treat with high dose corticosteroids', '8.3', 'Dose Modifications for Cisplatin, 5-FU, and/or Mitomycin ( Based on Interval Adverse', 'Events (occurring within a cycle of treatment)', 'Protocol Version Date: 21JUN2018']['MC1752', '35', 'Patients enrolled in this study will be evaluated clinically and with standard laboratory tests', 'before and at regular intervals during their participation in this study. This evaluation will', 'monitor for adverse events (all grades), serious adverse events, immune related adverse events,', 'and adverse events requiring study drug interruption or discontinuation at each study visit for the', 'duration of their participation in the study.', 'Concurrent chemo radiation is not expected to cause any immune related side effects. But since', 'the therapy is being combined with avelumab which can induce immune related side effects if', 'treating provider assessed an adverse event as immune related then it is recommended to perform', 'appropriate work up and confirming the nature of side effect.', 'It is expected to observe grade 3-4 gastrointestinal and genitourinary side effects with concurrent', \"chemo radiation. Symptom management as per best practices is recommended. It's appropriate to\", 'use growth factors for neutropenic complications.', 'CTCAE', 'System/Organ/Class', '(SOC)', 'ADVERSE EVENT', 'AGENT', 'ACTION', 'Febrile neutropenia', '(fever without', 'Delay chemotherapy by 1 week until ANC', 'clinically or', 'recovers to Grade 0-2 and until fever', 'Blood and lymphatic', 'microbiologically', 'Cisplatin', 'resolves.', 'disorders', 'documented', '5FU', 'Reduce dose by one level or more for', 'infection) [ANC', '<1.0 X 109 C/L]', 'subsequent cycles.', 'fever 38.3\u00b0C)', 'Left ventricular', 'systolic', 'Cisplatin', 'Dysfunction,', 'Grade 3 or higher hold chemotherapy until', '5FU', '.', 'myocardial', 'recovers to grade <1. .', 'Cardiac Disorders', 'infarction', 'Gastrointestinal', 'If not controlled with optimal medication.', 'Vomiting', 'Cisplatin,', 'disorders', '>Grade 3', '5FU', 'Reduce dose by one dose level and use', 'reduced level for subsequent cycles', 'Allergic reaction', 'Grade 1', 'Cisplatin ,', '5FU or', 'Stop infusion. After recovery restart the', '(eg, mild flushing,', 'infusion as per standard of care', 'Mitomycin', 'rash, pruritis)', 'Allergic reaction', 'Grade 2-3', 'Stop infusion. Give IV antihistamine', '(diphenhydramine 50 mg IV), IV H2-', 'Immune system', '(e.g. moderate rash,', 'Cisplatin ,', 'disorders', 'flushing, mild', '5FU or', 'receptor antagonist (famotidine 20 mg IV)', 'and steroid (dexamethasone 10 mg IV)', 'dyspnea, chest', 'Mitomycin', 'discomfort, mild', 'After recovery of symptoms resume', 'chemotherapy as per standard of care', 'hypotension)', 'Protocol Version Date: 21JUN2018']\n\n###\n\n", "completion": "END"}